December 18, 2013 | Israeli stem cell company Pluristem Therapeutics is moving forward with the agreement reached with Korean company CHA Bio & Diostech signed last June. The two companies have agreed on a strategic partnership which will also include a $10.4 million mutual investment via share swap.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments